Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: • High Profitability • Strong Liquidity • Low Leverage KRYS has exceptional profitability, liquidity, and minimal debt, but its premium valuation and slowing quarterly momentum warrant caution.
Price Behavior
Key Price Behavior Insights: • Positive monthly trend • Key support test • Breakout resistance Support Level: $351–$352 Resistance Level: $371–$372 KRYS remains constructively bullish over the last month but needs to hold $351–$352 and clear $371–$372 to resume upside after a sharp selloff.
Sentiment & News
Key News Insights: • Shares Rally • Vyjuvek Growth • Conference Catalyst KRYS gained on Vyjuvek growth and pipeline optimism, with investor attention shifting to its upcoming healthcare conference.
AI Summary
KRYS is now a profitable, cash-rich rare-disease commercial company, but at ~21x sales its premium valuation leaves little room for VYJUVEK growth to slow or pipeline readouts to disappoint; investors should favor holding/adding only if VYJUVEK penetration and European launches sustain growth while treating 2026 pipeline assets as upside optionality, not embedded value.
Description
Krystal Biotech is a clinical-stage biotechnology company developing redosable gene therapies for serious, primarily rare, dermatologic and genetic conditions. Its lead candidate, beremagene geperpavec (B-VEC), is in Phase III for dystrophic epidermolysis bullosa, while a portfolio of other programs spans early- and preclinical development for congenital ichthyosis, netherton syndrome, cystic fibrosis and multiple dermatology indications including aesthetic applications. The company was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Sep 3 | Sep 10 | KRYS | Krystal Biotech, Inc. | Rose 14.6% over 21 sessions and closed at the assessment-period high. Q2 VYJUVEK revenue reached $119.2 million, while 94.6% gross margin, strong profitability, international launches, and second-half 2026 clinical readouts support continuation. | Closed | -7.0% |
| Nov 3 | Nov 10 | KRYS | Krystal Biotech, Inc. | Selected as a speculative near-term buy ahead of Nov 3 earnings supported by FDA label expansion, upcoming European/Japanese launches, strong margins, and positive biotech sector trends, with cautious risk management due to seasonal sales softness and inventory build. | Closed | +0.9% |